Novartis AG ADR (NVS)vsNeuronetics Inc (STIM)
NVS
Novartis AG ADR
$138.99
-0.27%
HEALTHCARE · Cap: $260.70B
STIM
Neuronetics Inc
$2.80
-3.61%
HEALTHCARE · Cap: $207.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 36453% more annual revenue ($56.69B vs $155.10M). NVS leads profitability with a 22.5% profit margin vs -19.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
STIM
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$138.99
$45.70 premium
Margin of Safety
+80.2%
Fair Value
$9.10
Current Price
$2.80
$6.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
No standout strengths identified
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Trading at 12.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -131.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : STIM
STIM has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : STIM
The primary concerns for STIM are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 4.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while STIM is a turnaround play — different risk/reward profiles.
STIM carries more volatility with a beta of 1.17 — expect wider price swings.
STIM is growing revenue faster at 9.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 27/100), backed by strong 22.5% margins. STIM offers better value entry with a 80.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Neuronetics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?